Phathom Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 452
- Market Cap
- $1B
- Website
- http://www.phathompharma.com
- Introduction
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
VOQUEZNA Achieves $55.3M Revenue in First Full Year, Shows Strong Market Growth with 300,000 Prescriptions
Phathom Pharmaceuticals' VOQUEZNA generated $55.3 million in net revenue during 2024, with Q4 sales reaching $29.7 million, marking an 81% increase from Q3.
FDA Approves Phathom's Novel H. Pylori Treatments, Securing $260M Financing for Launch
Phathom Pharmaceuticals receives FDA approval for two vonoprazan-based combination therapies - Voquezna Triple Pak and Voquezna Dual Pak - for treating H. pylori infections.
Phathom Pharmaceuticals Presents New VOQUEZNA® Data at ACG 2024
Phathom Pharmaceuticals presented data at ACG 2024 highlighting VOQUEZNA's efficacy for Non-Erosive GERD, including on-demand use and nocturnal symptom relief.
Phathom Pharmaceuticals Presents New VOQUEZNA® Data for GERD Treatment at ACG 2024
Phathom Pharmaceuticals presented data on VOQUEZNA® (vonoprazan) at the ACG 2024 meeting, highlighting its efficacy in treating GERD.
Phathom Pharmaceuticals Presents Positive VOQUEZNA® Data for GERD Treatment at ACG 2024
Phathom Pharmaceuticals presented data on VOQUEZNA® (vonoprazan) at the ACG 2024 meeting, highlighting its efficacy in treating GERD.
FDA Approves Voquezna (vonoprazan) for Heartburn Relief in Non-Erosive GERD
The FDA has approved Voquezna (vonoprazan) 10 mg tablets for heartburn relief associated with Non-Erosive GERD in adults, marking a new option for millions.